Beam Therapeutics Inc. (BEAM) News
Follow Beam Therapeutics Inc. (BEAM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Anthropic AI Discovery Gene-Editing Stocks Falling
Gene-editing stocks fell Wednesday after Anthropic's Claude AI model identified an enzyme system with characteristics similar to technology used to alter DNA.Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Intellia
NEWS | Sep 24, 2026, 12:51 PM UTC
L
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
Gene-editing stocks sold off on Wednesday after Anthropic said its Claude model had flagged a phage enzyme system that shares a few design traits with CRISPR — the platform behind approved and experimental DNA-editing me
EQUITY | Sep 23, 2026, 09:49 PM UTC
L
Cathie Wood Makes Striking Switch Between AI Stock Giants
Cathie Wood's Ark Invest made a sharp rotation across technology and biotechnology stocks last week, buying roughly $28 million of Meta Platforms NASDAQ:META while selling a nearly identical dollar amount of Alphabet NAS
EQUITY | Sep 15, 2026, 12:21 PM UTC
L
BEAM: Durable gene editing advances in AATD, PKU, and sickle cell drive clinical and commercial momentum
Gene editing programs are advancing with strong clinical data in AATD, PKU, and sickle cell, leveraging base editing and integrated manufacturing. BEAM-302 shows durable efficacy and safety, while BEAM-304 and risto-cel
EQUITY | Sep 10, 2026, 01:40 PM UTC
L
BEAM: Gene editing pipeline advances with BEAM-302, BEAM-304, and risto-cel nearing pivotal milestones
The company is advancing a robust gene editing portfolio with lead programs in AATD, PKU, and sickle cell, leveraging next-gen base editing and integrated manufacturing. BEAM-302 and BEAM-304 show strong clinical and pre
EQUITY | Sep 10, 2026, 12:57 PM UTC
L
BEAM: Advancing pivotal gene editing programs with strong data, regulatory momentum, and platform scalability
Significant pipeline progress includes pivotal trials for AATD and sickle cell, with strong clinical data and regulatory alignment for accelerated approval. The platform enables rapid expansion to new indications, with a
EQUITY | Sep 09, 2026, 06:29 PM UTC
M
BEAM pipeline advances: pivotal trials progress in AATD and sickle cell
BEAM says pivotal trials are advancing for AATD and sickle cell, citing strong clinical data and regulatory alignment aimed at accelerated approval. The platform supports expansion into new indications and commercializat
EQUITY | Sep 09, 2026, 06:00 PM UTC
L
Beam Therapeutics price target held at $65 by Wedbush
Wedbush maintained a $65.00/share price target for Beam Therapeutics.
EQUITY | Sep 09, 2026, 12:19 PM UTC
M
Beam Therapeutics shares retreat after updated trial data disappoints
Beam Therapeutics shares fell 9% to $26.88 after the company shared updated trial data for BEAM-302 in alpha-1 antitrypsin deficiency.
EQUITY | Sep 08, 2026, 07:24 PM UTC
L
BEAM base editing platform advances toward commercialization
BEAM says its base editing platform enables precise, durable genetic corrections across multiple diseases, citing strong efficacy and safety data in alpha-1 antitrypsin deficiency and noting regulatory alignment for acce
EQUITY | Sep 08, 2026, 07:03 PM UTC
M
BEAM base editing platform reports robust efficacy and safety data
BEAM says its base editing platform delivers precise, durable genetic corrections and points to new efficacy and safety data in alpha-1 antitrypsin deficiency. Pivotal trials are progressing with regulatory alignment and
EQUITY | Sep 08, 2026, 06:31 PM UTC
M
BEAM-302 updated Phase I/II data show durable AAT restoration
Updated Phase I/II data for BEAM-302 in AATD report durable, functional AAT restoration, significant reduction of Z-AAT and Z-polymers, and a favorable safety profile. The pivotal global cohort is enrolling rapidly, with
EQUITY | Sep 08, 2026, 01:18 PM UTC
M
BEAM-302 shows durable AATD correction with favorable safety profile
BEAM-302 demonstrated durable, functional correction of AATD, with a favorable safety profile. In the 60 mg group, all patients maintained protective AAT levels, while the pivotal global cohort is enrolling rapidly.
EQUITY | Sep 08, 2026, 12:26 PM UTC
M
BEAM-302 shows durable efficacy and safety in AATD
BEAM-302 showed durable, one-time correction of AAT biology in AATD patients, achieving protective AAT levels, reducing disease-driving Z-AAT, and maintaining a favorable safety profile. Regulatory alignment supports an
EQUITY | Sep 08, 2026, 11:34 AM UTC
L
Beam Therapeutics presents updated Phase 1/2 BEAM-302 data at ERS 2026
Beam Therapeutics presented updated clinical data from its Phase 1/2 BEAM-302 trial for alpha-1 antitrypsin deficiency at the European Respiratory Society Congress 2026.
GEOPOLITICS | Sep 08, 2026, 10:00 AM UTC
L
Beam Therapeutics appoints Eric Foster as Chief Commercial Officer
Beam Therapeutics appoints Eric Foster as Chief Commercial Officer.
EQUITY | Sep 01, 2026, 11:00 AM UTC
L
BEAM - Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-30
BEAM - Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
EARNINGS | Aug 04, 2026, 11:00 AM UTC